In addition, immunomodulator therapies are mainly about anti-PD-L1 and PD-L1 antibodies.[49] In the case of anti-PD-1 and PD-L1 antibody therapy, the binding of PD-1 to its ligand PD-L1 weakens the activity of immunoregulatory T cells.[50,51] The application of blockers can restore immune activity in the tumor microenvironment and promote the maturation of DC cells and enhance the anti-tumor immune response.[52] In the future, this new signature can distinguish and evaluate the effect of these drugs, which greatly improves drug selection and maximum efficacy. Here, CD274 is linked to neoplasm.